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Signiﬁcant advances have been made over the past 25 years in our understanding of the most common
adult solid tumors such as breast, colon, lung and prostate cancer. Much less is known about childhood
solid tumors because they are rare and because they originate in developing organs during fetal de-
velopment, childhood and adolescence. It can be very difﬁcult to study the cellular origins of pediatric
solid tumors in developing organs characterized by rapid proliferative expansion, growth factor signal-
ing, developmental angiogenesis, programmed cell death, tissue reorganization and cell migration. Not
only has the etiology of pediatric cancer remained elusive because of their developmental origins, but it
also makes it more difﬁcult to treat. Molecular targeted therapeutics that alter developmental pathway
signaling may have devastating effects on normal organ development. Therefore, basic research focused
on the mechanisms of development provides an essential foundation for pediatric solid tumor transla-
tional research. In this article, we describe new resources available for the developmental biology and
oncology research communities. In a companion paper, we present the detailed characterization of an
orthotopic xenograft of a pediatric solid tumor derived from sympathoadrenal lineage during develop-
ment.
& 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Pediatric solid tumors have diverse molecular and cellular
features that reﬂect their unique cellular origins. With the recent
completion of sequence analysis of more than 1000 pediatric solid
tumor genomes, we now have a broad understanding of the
genomic landscape of childhood cancers that are derived from
mesodermal, ectodermal, and endodermal lineages (Downing
et al., 2012; Chen et al., in preparation). These data provide the
foundation to launch new research efforts to address a central
question in cancer biology: Why are cells of some lineages more
susceptible to malignant transformation at certain developmental
stages than are cells of other lineages? Due to their molecular,
cellular, developmental, and genetic diversity, pediatric solidInc. This is an open access article u
ental Neurobiology, MS 323,
homas Place, Memphis, TN
er).tumors provide an ideal platform on which to address this
question.
We have recently introduced a new unifying concept that we
call cellular pliancy, with broad implications for cancer suscept-
ibility and the developmental origins of pediatric solid tumors
(Chen et al., in preparation). To complement this new cellular
pliancy framework for answering fundamental questions about
cancer susceptibility and development, we have also established a
unique set of laboratory models with which to study childhood
solid tumors. To eliminate the barriers to developmental biologists
who are interested in studying the developmental origins and cell
biology of pediatric solid tumors, we have built a comprehensive
Childhood Solid Tumor Network (CSTN) that includes genomic and
other molecular data, cell lines, patient-derived orthotopic xeno-
grafts, and genetically engineered mouse models of childhood
solid tumors. All data, samples, and animal models are shared
freely through an online request form without obligation to col-
laborate. In this report, we describe the major pediatric solid tu-
mor types and the resources available through the CSTN. In ander the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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neuroblastoma orthotopic xenograft to provide an example of the
type of data and resources that are available through the CSTN.2. Ectodermally derived tumors
2.1. Retinoblastoma
Retinoblastoma is a rare cancer of the developing retina that is
usually diagnosed before 3 years of age. Retinoblastoma can be
hereditary or sporadic, and approximately 40% of patients have a
germline genetic defect in the retinoblastoma susceptibility gene,
RB1, that can lead to multiple tumor foci in each eye. The RB1 gene
is a tumor suppressor that regulates the cell cycle, differentiation,
and epigenetic processes (Dyer and Bremner, 2005; Macpherson
and Dyer, 2007; Dyer, in press). The cell of origin for retino-
blastoma has not yet been determined but is likely to be a retinal
progenitor cell that fails to cease proliferating during fetal devel-
opment (Dyer and Bremner, 2005; Macpherson and Dyer, 2007;
McEvoy et al., 2011). Importantly, individual tumor cells express
multiple retinal differentiation programs that are not normally
expressed at the same time in individual cells during retinal de-
velopment (McEvoy et al., 2011). This expression pattern is par-
tially due to epigenetic deregulation of retinal development; epi-
genetic perturbations also contribute to tumor progression (Zhang
et al., 2012). Retinoblastomas have relatively stable genomes and
some tumors have only RB1 gene mutations (Zhang et al., 2012;
McEvoy et al., in press). Overall, retinoblastomas are relatively
homogenous tumors with features of retinal neurons and pro-
genitor cells (McEvoy et al., 2011; Johnson et al., 2007). Genomic,
epigenomic, drug sensitivity, and gene expression data are avail-
able for human and mouse retinoblastomas. Also, human ortho-
topic xenografts, genetically engineered mouse models, and cell
lines are freely available through the CSTN.
2.2. Neuroblastoma
Neuroblastoma is the most common extracranial solid tumor in
children and can arise from any neural crest element of the sym-
pathetic nervous system (Cheung and Dyer, 2013). It most fre-
quently originates in one of the adrenal glands but can also de-
velop in sympathetic ganglia in the neck, chest, abdomen, or pelvis
(Cheung and Dyer, 2013). Most patients with neuroblastoma are
young (median age at diagnosis, 18 months) and approximately
40–50% have disseminated disease at ﬁrst presentation.
Ampliﬁcation of the MYCN oncogene is one of the most fre-
quent genetic lesions in neuroblastoma and is associated with
poor outcome (Brodeur, 2003). Germline mutations in the tran-
scription factor PHOX2B, which normally coordinates proliferation
and differentiation of the sympathoadrenal lineage during devel-
opment, can predispose children to neuroblastoma (Mosse et al.,
2004; Trochet et al., 2005; Raabe et al., 2008). Similarly, germline
mutations in the ALK gene can lead to perturbations in signal
transduction pathways in the same lineage and predispose chil-
dren to neuroblastoma (Chen et al., 2008; George et al., 2008;
Mosse et al., 2008). Neuroblastoma cells have molecular, cellular,
neuroanatomical, and neurochemical features of differentiated
neurons and accumulate catecholamines in dense core vesicles
(Cheung and Dyer, 2013). Indeed, catecholamine levels in urine are
measured to test for neuroblastoma. The recent discovery of re-
current somatic mutations in the ARID1A/1B genes (Sausen et al.,
2013), which encode chromatin remodeling proteins, and in the
ATRX gene, which encodes an ATP-dependent helicase (Cheung
et al., 2012), points to a role for epigenetics in neuroblastoma in-
itiation and progression. Neuroblastoma outcome is associatedwith the patient's age at diagnosis. Young children whose tumors
have favorable biology have excellent survival rates in excess of
90%; however, children older than 18 months at diagnosis have
only a 50% survival rate, which drops to 5% in patients aged 10
years or older at diagnosis (Mosse et al., 2014; London et al., 2005).
ATRX mutations are associated with the older age group, but it is
unclear whether they directly contribute to the poor outcome in
this patient population (Cheung et al., 2012; London et al., 2005).
Overall, neuroblastoma is a complex disease with multiple risk
factors that may reﬂect important differences in the develop-
mental origins of these tumors (Cheung and Dyer, 2013). Genomic,
epigenomic, drug sensitivity, and gene expression data are avail-
able for human neuroblastomas through the CSTN. Additionally,
gene expression and genomic data are available for genetically
engineered mouse models of neuroblastoma. Also, human ortho-
topic xenografts, genetically engineered mouse models, and cell
lines are available from the CSTN upon request.
2.3. Pediatric melanoma
Melanoma in children and adolescents accounts for less than
2% of all cases of melanoma (Wong et al., 2013). Although germline
mutations associated with xeroderma pigmentosum, Werner
syndrome, or retinoblastoma can predispose children and ado-
lescents to melanoma, most melanoma cases are sporadic
(Abramson et al., 1979; Pappo, 2003). As in adults, exposure to
sunlight at an early age increases the risk of melanoma (Strouse
et al., 2005; Whiteman et al., 1997). Recent genomic analysis
showed that most pediatric conventional melanomas are very si-
milar to adult melanomas, with oncogenic BRAF mutations, TERT
promoter mutations, and UV-induced DNA damage (Lu et al., in
press). Through the CSTN, genomic data and patient-derived xe-
nografts of pediatric melanoma are available.3. Mesodermally derived tumors
3.1. Osteosarcoma
Osteosarcoma is the most common type of bone cancer in
children and teens, arising most often in long bones such as the
femur, tibia, and humerus. However, it can also occur in ﬂat bones,
such as the pelvis and the skull, that support and protect vital
organs. Although most cases are sporadic, the risk of osteosarcoma
is increased in those with various genetic diseases, including
hereditary retinoblastoma, Li Fraumeni syndrome, and germline
mutations of RecQL4 (McIntyre et al., 1994; Hicks et al., 2007;
Kleinerman et al., 2005). Approximately 15–20% of patients have
metastatic disease at the time of diagnosis, with the lungs being
the most common site (Meyers et al., 1993).
Osteosarcomas occur most often in children and young adults,
and the peak age of diagnosis coincides with the onset of puberty.
Osteosarcoma is thought to arise from osteoblasts, with the rapid
expansion of this cell population during periods of growth con-
tributing to tumor initiation. It is also possible that changes in
hormone, cytokine, or chemokine levels associated with puberty
contribute to osteosarcoma initiation in adolescents and young
adults. Interestingly, children who have germline mutations in the
RB1 gene and develop retinoblastoma as infants are predisposed to
develop osteosarcoma in adolescence.
Virtually all osteosarcomas have initiating mutations in the
TP53 tumor suppressor gene, which is important for DNA repair,
stress response, and cell cycle progression (Chen et al., 2014). Of all
childhood cancers, osteosarcomas have the highest rate of chro-
mosomal breaks leading to structural variations and copy number
variations; they are thought to have unstable genomes and exhibit
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(Chen et al., 2014). Importantly, the mechanism of TP53 gene in-
activation is unique among human cancers: many osteosarcoma
tumors have translocations in the ﬁrst intron of the gene that
separate the promoter of the TP53 gene from the coding region,
generating an inactive allele (Chen et al., 2014; Miller et al., 1990).
This fact suggests that the cell of origin may have an inherently
unstable genome before the tumor initiates that becomes even
more unstable when p53 is inactivated.
Extensive genomic, epigenomic, drug sensitivity, and gene ex-
pression data of human and mouse osteosarcomas are available.
Also, human orthotopic xenografts, genetically engineered mouse
models, tissue blocks, and cell lines are available from the CSTN
upon request.
3.2. Ewing sarcoma
Ewing sarcoma is the second most common bone tumor in
children and adolescents and most commonly involves the axial
skeleton and the diaphysis of bones. Older patients have a higher
incidence of extraskeletal primary sites (Applebaum et al., 2011).
Ewing sarcoma is postulated to arise from the mesenchymal stem
cell-derived cellular lineages. Most Ewing sarcoma tumors have a
translocation involving the EWS gene on chromosome 22 and the
FLI gene on chromosome 11 (EWS-FLI) (Delattre et al., 1992). The
EWS-FLI oncoprotein alters expression of genes important for tu-
mor initiation and progression (Delattre et al., 1992; Lessnick and
Ladanyi, 2012). As with osteosarcoma, metastases are most com-
mon in the lung (Stahl et al., 2011). Ewing sarcomas have stable
genomes relative to those of osteosarcomas or other pediatric solid
tumors, and TP53 mutations are only found in a small subset of
patients' tumors (7%) (Tirode et al., in press). Indeed, in addition to
TP53, the only other signiﬁcant recurrent mutations in EWS are in
STAG2 (17%), which encodes part of the cohesion complex im-
portant for sister chromatid cohesion during M-phase of the cell
cycle, and CDKN2A (11%) (Tirode et al., in press), which encodes the
cell cycle regulation proteins p16INK4a and p14ARF (Sherr, 2001).
Patients with tumors harboring both STAG2 and TP53 mutations
have a poor clinical outcome (Tirode et al., in press). Ewing sar-
coma tumor cells have defects in DNA repair and are particularly
sensitive to PARP inhibitors when combined with DNA-damaging
agents (Chow et al., 1971).
The CSTN has genomic, epigenomic, drug sensitivity, and gene
expression data for human Ewing sarcoma. There are currently no
genetically engineered mouse models of Ewing sarcoma. However,
human orthotopic xenografts and cell lines are available from the
CSTN upon request.
3.3. Rhabdomyosarcoma
Rhabdomyosarcoma is the most common soft-tissue sarcoma
of childhood and adolescence (Reis et al., 1999). Rhabdomyo-
sarcoma can be divided into two broad histopathologic subtypes:
embryonal rhabdomyosarcoma (ERMS), which accounts for about
60% of all rhabdomyosarcomas, and alveolar rhabdomyosarcoma
(ARMS), which accounts for about 20% (Newton et al., 1988). The
remaining 20% of rhabdomyosarcomas cannot be unambiguously
assigned to either subtype. Patients with ERMS have a relatively
good prognosis, and their tumors are characterized by loss of
heterozygosity at the 11p15 locus (Scrable et al., 1989; Ognjanovic
et al., 2009). In contrast, patients with ARMS have an inferior
clinical outcome, and their tumors often contain a translocation
between the FOXO1A gene on chromosome 13q14 and either PAX3
on chromosome 2q35 or PAX7 on chromosome 1p36 (Barr, 1997;
Raney et al., 2001). Recent results suggest that translocation-ne-
gative ARMS tumors have molecular proﬁles more similar to thoseof ERMS tumors, so the current trend is to classify rhabdomyo-
sarcoma as being translocation-positive or translocation-negative
rather than in the histopathologic terms of ARMS and ERMS
(Williamson et al., 2010; Missiaglia et al., 2012).
Rhabdomyosarcoma tumor cells have features of muscle dif-
ferentiation, including abundant glycogen and myoﬁbrils. How-
ever, it is unclear whether the tumors arise from the muscle
lineage or from a more primitive cell that then adopts differ-
entiation features of muscle. For example, in mouse models, acti-
vation of the hedgehog pathway in brown fat cells can lead to
tumors with histopathologic features of ERMS (Hatley et al., 2012).
Translocation-positive rhabdomyosarcoma tumors have stable
genomes similar to those of the Ewing sarcoma tumors described
above, and they lack high rates of recurrent mutations in known
cancer or developmental pathways (Chen et al., 2013). In contrast,
the translocation-negative tumors have features of an unstable
genome, with the most recurrently mutated pathway being the
RAS signal transduction pathway (Chen et al., 2013). Those mu-
tations are associated with high-risk disease but their correlation
with outcome in translocation-negative rhabdomyosarcoma is
unknown (Chen et al., 2013).
We have established a large repository of ERMS and ARMS
genomic, epigenomic, drug sensitivity, and gene expression data
available in the CSTN. There are genetically engineered mouse
models available from other investigators, and some molecular
proﬁling has been carried out on those models. Human orthotopic
xenografts and cell lines are available from the CSTN upon request.4. Endodermally derived tumors
4.1. Hepatoblastoma
Similar to retinoblastoma, hepatoblastoma occurs in young
children (median age, 16 months) and is thought to arise from a
progenitor cell during development (Perilongo and Shafford, 1999;
Finegold et al., 2007).
Hepatoblastoma is a developmental cancer and is not asso-
ciated with prior hepatitis infection as is hepatocellular carcinoma
found in adults. However, patients with familial adenomatous
polyposis, Beckwith–Wiedemann syndrome, and trisomy 18 and
infants with very low birth weight (o1500 g) are at increased risk
for hepatoblastoma (Spector and Birch, 2012). Beta-catenin mu-
tations and deletions are common in embryonal and mixed sub-
types of sporadic hepatoblastoma (Lopez-Terrada et al., 2009).
Human orthotopic xenografts are available through the CSTN.5. Available resources
5.1. Molecular data
As part of the ﬁrst phase of the St. Jude Children's Research
Hospital – Washington University Pediatric Cancer Genome Pro-
ject (PCGP), a total of 286 tumors from 264 patients were analyzed
by whole-genome sequencing (WGS), and an additional 128 tu-
mors from 118 patients were analyzed by whole-exome sequen-
cing (WES). For adrenal cortical carcinoma, there were 21 tumor
samples from 20 patients for WGS and 19 tumors from 19 patients
for WES. For neuroblastoma, there were 63 tumor samples from
58 patients for WGS and 49 tumor samples from 48 patients for
WES (Cheung and Dyer, 2013; Cheung et al., 2012). For osteo-
sarcoma, there were 50 tumor samples from 40 patients for WGS
and 2 tumor samples from 2 patients for WES (Chen et al., 2014).
For pediatric melanoma, 7 tumor samples from 5 patients were
sequenced by WGS and 15 tumor samples from 14 patients for
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from 15 patients and 1 matched orthotopic xenograft were ana-
lyzed by WGS (Zhang et al., 2012; McEvoy et al., in press). For
rhabdomyosarcoma, 16 tumor samples from 13 patients were
analyzed by WGS and 42 tumor samples from 34 patients were
analyzed by WES (Chen et al., 2013). For Ewing sarcoma, 113
samples from 113 patients were analyzed by WGS. Summary data
for these tumors are available at http://explorepcgp.org/. For
speciﬁc gene mutations or pathway analysis, submit a request to
https://hospital.stjude.org/dbstp/. All raw data can be obtained
through the European bioinformatics website www.ebi.ac.uk as
follows:Adrenocortical Carcinoma: EGAD00001000160
Neuroblastoma: EGAD00001000135
Osteosarcoma: EGAD00001000159
Retinoblastoma: EGAD00001000261
Rhabdomyosarcoma: EGAD00001000164
Ewing Sarcoma: EGAS00001000855, EGAS00001000839As part of the second phase of the St. Jude Children's Research
Hospital – Washington University Pediatric Cancer Genome Pro-
ject (PCGP) project, integrated epigenetic proﬁling will be per-
formed on orthotopic xenografts derived from pediatric solid tu-
mors. WGS, WES, RNA-Seq, and whole-genome bisulﬁte sequen-
cing (WGBS) will be performed on the patient tumor samples.
Those data will be compared to WGS, WES, RNA-Seq, and WGBS
data of orthotopic xenografts derived from the patient samples.
Integrated epigenetic analysis will then be performed on the xe-
nografts by ChIP-seq for RNA-Pol II, 5-hmC, BRD4, CTCF, ATRX, and
8 histone marks. All of the xenografts are freely available to the
community, and the epigenetic data will be made available as it is
validated. The pediatric solid tumor types analyzed in the second
phase of the PCGP include rhabdomyosarcoma, neuroblastoma,
Ewing sarcoma, osteosarcoma, retinoblastoma, adrenocortical
carcinoma, rhabdoid tumor, liposarcoma, and non-rhabdo soft-
tissue sarcoma.
5.2. Drug sensitivity data
In collaboration with investigators in the Department of Che-
mical Biology and Therapeutics at St. Jude Children's Research
Hospital, we have performed high-throughput drug screening
with pediatric solid tumor cell lines and primary cultures of or-
thotopic xenografts. Each cell line and xenograft was individually
optimized for plating density and sensitivity to the drugs' diluent
(DMSO). Once the growth conditions were optimized, a positive-
control, cytotoxic-agent selection plate is used to identify 2 cell-
type-speciﬁc positive-control compounds. A negative control (i.e.,
DMSO) was also included in all plate runs; and 3 independent,
triplicate validation runs with positive and negative controls must
pass quality control before drug testing. All data on growth con-
ditions, DMSO sensitivity, validation, and QC for each line are
available. The drug screening was performed in triplicate in dose
response with an automated curve classiﬁcation and curve-ﬁtting
algorithm. In addition to the pediatric solid tumor cells, we also
used a variety of negative control cell lines such as BJ and HepG2.
Available drug sensitivity data for cell lines and xenografts will be
sent with EC50, curve class, and drug name upon request.
To date, 5 different rhabdomyosarcoma cell lines and 10 dif-
ferent orthotopic xenografts have been tested with the oncology
drug set and the rhabdomyosarcoma targeted drug set (Table S1).
For Ewing sarcoma, 4 cell lines have been tested and 1 xenograft
has been tested with the oncology drug set, the rhabdomyo-
sarcoma drug set, and the Ewing drug set (Table S1). For osteo-
sarcoma, 2 cell lines and 4 xenografts have been tested with therhabdomyosarcoma, HDAC, and oncology drug sets. For neuro-
blastoma, 8 cell lines, and 1 xenograft have been tested with the
oncology drug set. For retinoblastoma, 3 cell lines have been tested
with the oncology and HDAC drug sets.
5.3. Cell lines
Cell lines have been created from a variety of primary tumor
samples at St. Jude. In addition, we have characterized a series of
pediatric solid tumor cell lines available through the ATCC. Several
of the lines have been genetically engineered to express ﬁreﬂy
luciferase, so the resulting tumors can be monitored in vivo using
the Xenogen imaging system. These cell lines are available as
cryogenically frozen viable cells or fresh frozen pellets for mole-
cular analyses. All lines have been mycoplasma-tested and vali-
dated by genotyping at the time of cryopreservation. A complete
list of available cell lines can be found at: https://hospital.stjude.
org/dbstp/
5.4. Orthotopic xenografts
Primary tumor material was collected at St. Jude Children's
Research Hospital after informed consent and in agreement with
local institutional ethical regulations under the Molecular Analysis
of Solid Tumors (MAST) protocol. The protocol opened on January
21, 2010, and over 150 patients were accrued in the ﬁrst 4 years.
Xenografts have been created from primary tumors that have been
orthotopically implanted into immunocompromised mice (NSG
strain) and then passaged from mouse to mouse. The primary
tumors are dissociated by enzymatic treatment and titruation
prior to orthotopic injection. Detailed procedures for orthotopic
injection and tumor dissociation are available through the CSTN
(https://hospital.stjude.org/dbstp/).
Several hundred vials are cryopreserved at an early passage and
then the xenograft is completely characterized at that passage as
described above for Phase II of the PCGP. Most of the xenografts
have been modiﬁed to express ﬁreﬂy luciferase to enable mon-
itoring of tumor engraftment and progression by using Xenogen
imaging. In addition to cryopreserved xenografts, fresh frozen
tissue, and formalin-ﬁxed parafﬁn-embedded tissue blocks of each
xenograft are also available. Currently, there are 17 osteosarcomas,
15 rhabdomyosarcomas, 9 neuroblastomas, 6 retinoblastomas,
4 hepatoblastomas, 3 pediatric melanomas, 2 non-rhabdo soft-
tissue sarcomas, and 1 sample each of adrenocortical carcinoma,
Ewing sarcoma, rhabdoid tumor, and liposarcoma.
5.5. Genetically engineered mouse models
Genetically engineered mouse models of pediatric solid tumors
are available through the CSTN. The genetic models are available as
live mice, tissue blocks, and ﬂash-frozen tumor tissue. For some
models, we also have gene expression array data and genomic/
epigenomic characterization data.
Six genetically engineered mouse models of retinoblastoma are
available through the CSTN (McEvoy et al., 2011; Benavente et al.,
2013). All models use the same retinal progenitor cell-speciﬁc Cre-
transgene (Chx10-Cre) and different combinations of null or ﬂoxed
alleles of the Rb family with p53 pathway inactivation:Chx10-Cre;Rblox/Lox;p107–/–
Chx10-Cre;Rblox/Lox;p107–/–;p53lox/Lox
Chx10-Cre;Rblox/Lox;p107–/–;p130lox/Lox
Chx10-Cre;Rblox/Lox;p130–/–
Chx10-Cre;Rblox/Lox;p107–/–;MDMXTg
Chx10-Cre;Rblox/Lox;p107þ /–;p130–/–
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based on conditional inactivation of the Rb and p53 pathways in
osteoblasts (Walkley et al., 2008). Three genetically engineered
mouse models of osteosarcoma are available through the CSTN:Ostx-Cre;Rblox/Lox;p53Lox/Lox
Ostx-Cre;Rblox/Lox;p53Lox/Lox;p107–/–
Ostx-Cre;Rblox/Lox;p53Lox/Lox;ATRXLox/LoxMost of the genetically engineered mouse models of neuro-
blastoma are based on the original MYCN transgenic strain (Weiss
et al., 1997). More recently, new models of neuroblastoma have
been developed that include mutations in Alk (Zhu et al., 2012;
Schulte et al., 2012) and Lin28b (Molenaar et al., 2012). We have
also included Atrxmutations to model the indolent form of disease
in Stage 4 patients older than 12 years (Cheung et al., 2012). The
available strains are as follows:TH-MYCN
TH-MYCN;RosaLoc/Luc;TH-Cre;Caspase8Lox/Lox
TH-MYCN;AtrxLox/Lox;TH-CreEfforts are underway to generate the following additional
strains:TH-MYCN;Lin28bLSL;DBH-iCre
TH-MYCN;TH-ALKF1174L
TH-MYCN;AtrxLox/Lox;DBH-iCre
TH-MYCN;Lin28bLSL;AtrxLox/Lox;DBH-iCre
TH-MYCN; AtrxLox/Lox;DBH-iCre;TH-ALKF1174L
Lin28bLSL;AtrxLox/Lox;DBH-iCre
AtrxLox/Lox;DBH-iCre;TH-ALKF1174L5.6. OpenClinica
In collaboration with investigators in the Department of Radi-
ological Sciences at St. Jude Children's Research Hospital, we have
developed a preclinical phase I–III system modeled after the
clinical practices system to store and analyze data from our pre-
clinical studies in mice. Preclinical phase I studies are designed to
test the tolerability of drug combinations administered at clinically
relevant doses and schedules. Appropriate measures of toxicity are
incorporated into the studies on the basis of side effects in chil-
dren. Preclinical phase II studies are randomized studies with
small numbers of mice (5/treatment group) to identify drug
combinations with any evidence of efﬁcacy for more detailed
analyses. Preclinical phase III studies are double-blind, rando-
mized, placebo-controlled studies with sufﬁcient numbers of mice
in each treatment group to provide statistical power for the study.
Data from these preclinical trials are entered into OpenClinica
(Isovera, MA, USA) for data capture and management. Mice used in
preclinical studies received a mouse medical record number
(mMRN) and all data, including mouse weight, chemotherapy drug
(s) and dose(s) received, diagnostic imaging, and end-of-therapy
evaluation are recorded for each mouse. Histologic, X-ray, MRI,
Xenogen, PET–CT, and macro-images of the mice are also available.
5.7. Pharmacokinetics
Through the Preclinical Pharmacokinetics Shared Resource at
St. Jude Children's Research Hospital, we have performed plasma
and tumor pharmacokinetic studies for several high-priority drugs
that are in development for pediatric solid tumors. A report for
each drug that includes the assay procedure and assay validation
and reproducibility data is available through the CSTN (https://hospital.stjude.org/dbstp/). Pharmacokinetic models of the data
with area under the curve calculations are also included, as is
conversion of the human dose to a murine equivalent dose based
on the plasma pharmacokinetic parameters. Pharmacokinetic data
are available for olaparib, sorafenib, pazopanib, everolimus, fos-
tamatinib, linsitinib, dactolisib, buparlisib, panobinostat, veliparib,
and talazoparib. The plasma pharmacokinetic data are compared
to the human data and used to calculate a murine equivalent dose.
The tumor pharmacokinetic data are used to determine whether
sufﬁcient levels of drug penetrate the tumor to achieve a sig-
niﬁcant anti-tumor effect.6. Summary
Oncogenes and tumor suppressor genes that initiate and pro-
mote tumorigenesis also have important roles in normal devel-
opmental processes. Thus, as individual cells undergo malignant
transformation, they may simultaneously undergo changes in cell-
fate speciﬁcation and differentiation. For example, RB1 inactivation
contributes to retinoblastoma initiation by promoting cell-cycle
progression, but the RB1 protein is also required for rod photo-
receptor differentiation (Zhang et al., 2004). It is important to
emphasize that these roles are cell-type and developmental stage-
speciﬁc and that there are similar examples for virtually every
well-characterized oncogene and tumor suppressor gene.
The other important consideration with respect to cellular di-
versity and malignant transformation relates to developmental
competence (Cepko et al., 1996). Pediatric solid tumors arise in
complex and dynamic developing tissues as multipotent pro-
genitor cells are undergoing unidirectional changes in their in-
trinsic competence to produce differentiated cell types. These are
some of the most dynamic and robust cellular events in biology
and pose unique challenges when trying to identify the cellular
origin of pediatric solid tumors. For example, different cellular
populations of mesodermally derived progenitor cells may be
heterogeneous with respect to their developmental bias toward
muscle, adipose, or osteogenic cell fates. When a tumor-initiating
mutation occurs in those distinct progenitor cell populations, the
result may vary dramatically depending on the competence of that
cell at that particular stage of development. In one cell population,
an oncogenic mutation may result in a tumor with cellular fea-
tures of skeletal muscle such as rhabdomyosarcoma. In another
cell population, the same oncogenic mutation may lead to rapid
cell death or, alternatively, to a tumor with osteogenic features.
Thus, the competence of individual progenitor cells combined
with the speciﬁc oncogenic mutations inﬂuence when and where
pediatric solid tumors arise during development.
To support basic research on pediatric solid tumors, we have es-
tablished the Childhood Solid Tumor Network. The goal is to provide
well-characterized and comprehensive datasets and validated biolo-
gical specimens and animal models for basic research. We believe that
engaging developmental biologists in childhood solid tumor research
is essential to advance our understanding of these devastating ma-
lignancies. The innovations in molecular, cellular, and computational
biology that are widely used in the developmental biology community
have the potential to fundamentally reshape the way we develop new
therapies for children with cancer. The expertize in drug development
and drug discovery, pharmacokinetics, pharmacodynamics, preclinical
testing, and clinical trial development is currently in place. However,
outstanding basic research into the developmental origins of pediatric
solid tumors and an understanding of the interplay between cellular
competence, lineage speciﬁcation, and malignant transformation is
needed. We hope that the CSTN will emerge as the central nexus for
sharing of data, expertize, and resources for basic and translational
research on pediatric solid tumors.
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To request samples, data, mice and/or protocols, visit https://
hospital.stjude.org/dbstp/ and ﬁll out the online request form.
There is a streamlined MTA/CDA process and once those docu-
ments are executed, samples and/or data will be sent to the re-
questor. There is no cost to request samples except for shipping
fees. There is no obligation to collaborate even for unpublished
data/samples.Bimonthly newsletter
We provide updates on samples, protocols, basic, translational
and clinical research in a bimonthly newsletter. If you would like
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